Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months~* Inadequate response or limiting side effects with pharmacotherapy for the treatment of OAB~Exclusion Criteria:~* Overactive Bladder caused by neurological condition~* Patient has predominance of stress incontinence~* History or evidence of pelvic or urological abnormality~* Prior use of BOTOX for any urological condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 100U cohort - BOTOX® plus Hydrogel admixture (Type: EXPERIMENTAL): 100U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 100U cohort - Placebo plus Hydrogel admixture (Type: PLACEBO_COMPARATOR): Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 300U cohort - BOTOX® plus Hydrogel admixture (Type: EXPERIMENTAL): 300U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 300U cohort - Placebo plus Hydrogel admixture (Type: PLACEBO_COMPARATOR): Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 400U cohort - BOTOX® plus Hydrogel admixture (Type: EXPERIMENTAL): 400U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 400U cohort - Placebo plus Hydrogel admixture (Type: PLACEBO_COMPARATOR): Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 500U cohort - BOTOX® plus Hydrogel admixture (Type: EXPERIMENTAL): 500U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
- 500U cohort - Placebo plus Hydrogel admixture (Type: PLACEBO_COMPARATOR): Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).